Articles On Recce Pharmaceuticals (ASX:RCE)

Highlights ASX 200 and small caps show steady gains Mining and energy sectors capture attention Key project expansions in Australia and abroad Overview of ASX 200 and Small-Cap Movements The ASX stock market saw modest gains as t...

ASX edges up just 10.8 points or 0.13% Gold holds steady with minor lift overnight as iron ore dips Broad losses in energy as analysts predict supply glut over next 24 months   Info tech fuels fourth day of gains Four sessions of tech-dri...

Highlights International Graphite progresses land acquisition for a commercial graphite micronising plant in Western Australia. Recce Pharmaceuticals gains a key Hong Kong patent, strengthening protection for its anti-infective drug ca...

Patent Family 4 granted in Hong Kong for Recce’s anti-infectives R327 and R529 Recce now has six Family 4 patents granted with other countries including Australia, Canada, Israel, Japan and China This new patent strengthens Recce’s intelle...

Highlights ASX benchmark rises with wider participation from small caps AI adoption trends shine a light on new growth paths Multiple companies update exploration, energy and technology activities The Market Outlook: ASX Pushes Hi...

ASX shrugs off hot CPI read, closes up 0.81% Gold, lithium, rare earths lead resources gains Broad upward momentum across eight sectors   Gold and lithium build momentum Lion Selection Group (ASX:LSX) MD Hedley Widdup predicted Australia...

Recce’s R327 demonstrates significant antibacterial activity against multidrug-resistant pathogen Acinetobacter baumannii Considered one of the most challenging and antibiotic-resistant bacteria associated with hospital acquired infection...

Recce Ltd (ASX:RCE) has released news that its flagship antibacertial and anti-infective drug, R327, has in a simulated model shown the drug could technically be effective as an inhalant, which would add another mechanism by which Recce can...

Highlights R327 shows strong effect against resistant lung infections Nebulised delivery enhances practical hospital use Expanding research program strengthens anti-infective pipeline Recce Pharmaceuticals Ltd (ASX:RCE) has recent...

Anti-infectives house Firebrick Pharma reveals what shareholders think of the company – warts and all Pot play Vitura blooms in the September quarter Recce claims early victory in war against superbugs   In the spirit of being truthful a...

Host Tylah Tully looks at Recce Pharmaceuticals (ASX:RCE) in the latest episode of Who’s Who on the ASX. Recce is a clinical-stage biotech company focused on developing a new class of synthetic anti-infectives. In particular, the company is...

Recce Pharmaceuticals (ASX:RCE) has been progressing its way – or that for its flagship breakthrough anti-infective drug, R327 – through the checkbox-heavy process of accumulating clinical data for regulatory validation. And with a Phase 3...

Amid soaring global tensions, investors have flocked to the best known local defence stocks ASX-listed companies have snared military contracts for goods and services including counter drone services, AI, virtual reality and high-tech lase...

Recce Pharmaceuticals (ASX:RCE) has taken a leap forward as it works towards creating the world’s first dedicated diabetic foot infection treatment, with patient dosing starting in its third-phase clinical trial in Indonesia this week. L...

Patient dosing is underway for Recce’s registrational Phase 3 trial of R327G for diabetic foot Infections Five sites activated in Indonesia, which has one of the world’s largest patient populations of diabetic foot infections Interim anal...

Highlights Recce Pharmaceuticals advances Phase 3 trial. Nickel Industries strengthens financial position. Premier Industries and Liontown Resources experience declines. This article provides an in-depth analysis of the ASX 200, h...

Recce Pharmaceuticals (ASX: RCE) has commenced patient dosing for a registrational Phase 3 clinical trial of its RECCE 327 topical gel (R327G) to treat diabetic foot infections (DFI). The company has activated five clinical study sites acro...

The Recce 327 Topical Gel is “highly effective” for treating infected burn wounds – and it works quickly too – Recce Pharmaceuticals (ASX:RCE) confirmed in ongoing tests, setting the stage for a U.S. Defence partnership. Listen to the Ho...

  Highlights The benchmark index closed at a new high following the central bank’s latest rate adjustment Major banking stocks recorded gains as lenders adjusted variable loan rates Utilities, consumer discretionary, and fi...

RBA cuts interest rates by 25 basis points ASX notches new all-time intraday and closing highs Broad market strength with 8 of 11 sectors green   ASX breaks through 8870 points The ASX 200 set both a new intraday high (8885) and a new rec...

Recce’s R327G highly effective against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infected wounds (in-vivo) R327G efficacy outcomes statistically significant and consistently superior to comparator antibiotic So...

Recce Pharma (ASX:RCE) has notched modest gains on Tuesday arvo after reporting its R327 anti-infective gel was effective on burn wounds in an in-vivo model. Listen to the HotCopper podcast for in-depth discussions and insights on all th...

 Advances on research and development tax incentives are proving a popular source of ancillary financing Audeara shares surge up to 36% on China deal Bell Potter halves its Syntara valuation   With traditional equity fundraising conditio...

Highlights: Energy sector focus drives activity in ASX small-cap space Gold exploration remains in spotlight amid resource updates Tech solutions companies show contract and expansion developments The ASX small-cap lan...

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

ASX slips 0.04pc, pushed lower by utilities sector Gold index props up materials sector, adding 1.11pc Uranium stocks continue to climb The Australian market slid in the face of global headwinds today, losing 0.04%. Most of the sectors we...

Recce Pharmaceuticals (ASX:RCE) has secured the first tranche of a $30 million debt facility to continue running skin infection trials and boost commercialisation efforts across the ASEAN region. Listen to the HotCopper podcast for in-d...

Recce establishes debt facility of up to ~$30m with Avenue Capital Group Initial non-dilutionary funding of ~$11.5m supporting two registrational Phase III clinical trials Debt facility builds on Recce’s recent ~$15.8m capital raise, stre...

Tylah Tully chats with Recce Pharmaceuticals (ASX:RCE) managing director and CEO James Graham about the company’s recent placement.  Recce’s raised $7.4 million in an entitlement offer shortfall, the final part of a broader $15.8 million c...

Recce Pharmaceuticals (ASX:RCE) has successfully filled its coffers ahead of its Phase III clinical trials in Indonesia and Australia, with the company this week landing “firm commitments” to place the full shortfall in its capital raise....

Recce entitlement offer shortfall placed to existing institutional and sophisticated investors, raising $7.4 million Shortfall placement concludes Recce’s $15.8 million capital raising to support phase III clinical trials in Indonesia and...

Recce secures patent acceptance in China for anti-infectives Acceptance strengthens the company’s global patent portfolio Recce tackling global health problem of antibiotic-resistant superbugs   Special Report: Recce Pharmaceuticals has...

ASX health stocks up 0.57% over past week, while the broader market is up 0.35%  Wave of capital raisings as ASX-listed healthcare firms seek to strengthen their balance sheets Monash IVF’s woes continue with company downgrading FY25 blami...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Research reports on ASX-listed companies, to download in full. **** -Airtasker ((ART...

ASX falls almost 1pc on Monday after setting new 20-day high last week Sectors in the red right across the board Falling oil price weighs heavily on Energy sector, down more than 2.8pc   An eighth day of gains just wasn’t to be for the AS...

Highlights US markets extend gains, driven by trade optimism and strong corporate earnings. The Australian market remains stable, with financial and materials sectors seeing limited movement. Local focus turns to CPI data, w...

Life science companies are turning to federal research & development tax refund advances to stave off capital raisings on unfavourable terms Biotechs undergoing eligible R&D know they will receive a federal R&D rebate, but ther...

Recce receives HREC approval to expand its Phase II clinical trial for diabetic foot infections Approval allows up to 20 additional patients access to access its R327G treatment Follows recently released positive Phase II clinical trial d...

Recce Pharmaceuticals (ASX:RCE) has received a boost to the development of its topical gel for the treatment of diabetic foot infections, as 20 more patients with the condition are added to its Phase II clinical trial of the product, R327G....

Oil prices lift almost 2pc, boosting energy sector Gold reaches all-new highs of $US3,332 per ounce, pushing ASX Gold index higher Strength in rare earths lifts small cap index and materials sector   Energy and resources stocks have been...

Highlights: Recce Pharmaceuticals initiates a two-part capital raise to support advanced clinical trials Funding allocated to clinical programs focused on diabetic foot and bacterial skin infections Trials to be conducted ac...

Recce Pharmaceuticals Ltd (ASX:RCE) is aiming to complete a capital raising of $15.8 million to funds its clinical trials in Indonesia and Australia through a $5M Placement to a private investor and $10.8M Entitlement Offer to shareholders....

Funding to support Phase III clinical trials for diabetic foot infections and acute bacterial skin and skin structure infections Private Australian-based investor has subscribed for $5 million shares via a placement A$10.8 million entitlem...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

A ginger group of Mayne Health shareholders argues Cosette’s $600 million offer isn’t the right prescription Artrya gets to the heart of the matter after FDA approval Zelira Therapeutics goes to the ATM for $1 million   US healthcare grou...

Superbug-buster Recce has bucked the trend by targeting Indonesia as the host of its planned phase III diabetic foot ulcer trial Recce’s synthetic antibiotic candidate seeks to overcome the problem of antimicrobial resistance A local phase...

ASX slides again, seven losses in eight days Copper tariff talk spooks miners, Rio and BHP down Woolies, Platinum, and Flight Centre also take a hit   It was another rocky ride for local stocks today, with the ASX 200 benchmark down by 0....

Banks drag as Bendigo, Westpac slump Star Entertainment Group jumps on $650m refinancing Jack Ma’s return sparks tech rally in China   The ASX retreated by about 0.37% from Friday’s record high, with banks pulling the market down on Monda...

Recce Pharmaceuticals (ASX: RCE) has released positive patient data analysis from a Phase II clinical trial of its Recce 327 topical gel (R327G) for the treatment of acute bacterial skin and skin structure infections. The company designed t...